# Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions

> **NCT00625521** · PHASE2 · COMPLETED · sponsor: **Astion Pharma A/S** · enrollment: 32 (actual)

## Conditions studied

- Discoid Lupus Erythematosus

## Interventions

- **DRUG:** ASF 1096 0.5 % cream applied twice daily
- **DRUG:** Cream vehicle for ASF 1096 cream applied twice daily

## Key facts

- **NCT ID:** NCT00625521
- **Lead sponsor:** Astion Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2008-02-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625521, "Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00625521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*